Frédéric Vanhoutte

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)

René Westhovens, Peter C. Taylor, Rieke Alten et al. · Annals of the Rheumatic Diseases · 2016 · 227 citations · Full text

Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)

Arthur Kavanaugh, Joel M. Kremer, L Ponce et al. · Annals of the Rheumatic Diseases · 2016 · 226 citations · Full text

Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study

M. Bhushan, A. David Burden, Kathleen McElhone et al. · British Journal of Dermatology · 2001 · 120 citations

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials

Frédéric Vanhoutte, Minodora Mazur, O.I. Voloshyn et al. · Arthritis & Rheumatology · 2017 · 75 citations · Full text

Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers

Andi Leubitz, Anat Frydman‐Marom, Neal Sharpe et al. · Clinical Pharmacology in Drug Development · 2019 · 69 citations · Full text